Dr. Li Jianwei (李建伟) joined our Group on October 14, 2020 and served our chief technology officer and the chief operating officer of Cellularforce from October 2020 to February 2023. He has been serving as the chief operating officer and deputy general manager of our Company and general manager of Cellularforce since March 2023. He is mainly responsible for the R&D, GMP manufacturing, quality management and general operation of our Group.

Dr. Li has over 14 years of experience in biotechnology and pharmaceutical industries,leading the R&D and GMP manufacturing of therapeutic recombinant proteins. Prior to joining our Group, he once worked at Symyx Technologies Inc., a company mainly engaged in developing high-throughput technologies for screening catalysts and API leads whose shares are listed on NASDAQ (stock code: SMMX), and Syagen Technology Inc., a subsidiary of Smiths Group plc, a company mainly engaged in developing portable mass spectrometers for fast field detection of bio-organic weapons and drugs whose shares are listed on the London Stock Exchange (stock code: SMIN). From August 2007 to November 2014, Dr. Li served as the principal scientist at Allergan, Inc. (currently known as AbbVie Inc.), a global pharmaceutical company whose shares are listed on NASDAQ (stock code: ABBV). From April 2016 to August 2020, Dr. Li served as a vice president of process development and manufacturing department at Sorrento Therapeutics Inc., a clinical-stage antibody-centric biopharmaceutical company whose shares are listed on NASDAQ (stock code: SRNE).

Dr. Li graduated from Shanghai University of Technology (上海工业大学) (currently known as Shanghai University (上海大学)) in the PRC with a bachelor’s degree in metallurgical engineering in October 1982 and a master’s degree in applied chemistry in May 1988. He further received his doctoral degree (PH.D.) of Philosophy from University of Berne in Switzerland in December 1993.